Xigris "Dear Doctor" Letter Follows Termination Of Pediatric Sepsis Trial

Lilly says a data monitoring committee determined that Xigris was "highly unlikely to show improvement over placebo" in the study's primary endpoint – composite time to complete organ failure resolution.